ANAB vs XOMA
ANAB: AnaptysBio is a streamlined royalty management company focused on maximizing the value of long-term financial collaborations for therapeutic antibodies like Jemperli. XOMA: A lean-infrastructure royalty aggregator that generates non-dilutive capital for biotech developers in exchange for long-duration milestone and royalty rights across a diversified 120+ asset portfolio spanning oncology, rare disease, and specialty therapeutics.
Side-by-side fundamentals
| Metric | ANAB | XOMA | Edge |
|---|---|---|---|
| Price | $46.21 | $40.17 | |
| Market cap | $1.3B | $504M | |
| P/E as of 2026-07-21 | n/a | 20.04 | |
| Net margin FY2025, SEC XBRL | -5.6% | +60.8% | XOMA higher |
| Operating margin FY2025, SEC XBRL | +20.4% | +21.8% | XOMA higher |
| ROE FY2025, SEC XBRL | -35.6% | +37.8% | XOMA higher |
| ROA FY2025, SEC XBRL | -3.6% | +11.6% | XOMA higher |
| Debt / equity as of 2026-09-03 | 20.69 | 0.91 | XOMA lower |
| Revenue growth (YoY) as of 2026-09-03 | +107.7% | +13.2% | ANAB higher |
| Revenue CAGR (3y) SEC XBRL | +183.6% | +105.3% | ANAB higher |
| Dividend yield as of 2026-09-02 | n/a | +0.8% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-03 | 0.73 | 0.96 | |
| 1-year return | +117.8% | +57.7% | ANAB higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.